TY - JOUR. T1 - Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study. AU - Rajan, Kumar B.. AU - Aggarwal, Neelum T.. AU - McAninch, Elizabeth A.. AU - Weuve, Jennifer. AU - Barnes, Lisa L.. AU - Wilson, Robert S.. AU - DeCarli, Charles. AU - Evans, Denis A.. PY - 2020. Y1 - 2020. N2 - Objective: The longitudinal association of the blood biomarkers total tau (t-tau), neurofilament light (Nf-L), and glial fibrillary acidic protein (GFAP) with common sporadic Alzheimer disease (AD) and cognitive decline is not established. Methods: Using a single molecule array technology, ultrasensitive immunoassays for serum concentrations of t-tau, Nf-L, and GFAP were measured in a population sample of 1,327 participants (60% African Americans and women) who had a clinical evaluation for AD, had completed in-home cognitive assessments, and had undergone 1.5T structural magnetic resonance imaging. Results: Higher concentrations of serum biomarkers were associated with the development ...
Using published dairy cattle liver transcriptomics dataset along with novel blood biomarkers of liver function, metabolism, and inflammation we have attempted an integrative systems biology approach applying the classical functional enrichment analysis using DAVID, a newly-developed Dynamic Impact Approach (DIA), and an upstream gene network analysis using Ingenuity Pathway Analysis (IPA). Transcriptome data was generated from experiments evaluating the impact of prepartal plane of energy intake [overfed (OF) or restricted (RE)] on liver of dairy cows during the peripartal period. Blood biomarkers uncovered that RE vs. OF led to greater prepartal liver distress accompanied by a low-grade inflammation and larger proteolysis (i.e., higher haptoglobin, bilirubin, and creatinine). Post-partum the greater bilirubinaemia and lipid accumulation in OF vs. RE indicated a large degree of liver distress. The re-analysis of microarray data revealed that expression of ,4,000 genes was affected by diet x ...
TY - JOUR. T1 - Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimers Disease Risk. AU - Leifert, Wayne R.. AU - Nguyen, Tori. AU - Rembach, Alan. AU - Martins, Ralph. AU - Rainey-Smith, Stephanie. AU - Masters, Colin L.. AU - Ames, David. AU - Rowe, Christopher C.. AU - Macaulay, S. Lance. AU - François, Maxime. AU - Fenech, Michael F.. AU - The AIBL Research Group. PY - 2015/9/9. Y1 - 2015/9/9. N2 - Mild cognitive impairment (MCI) may reflect early stages of neurodegenerative disorders such as Alzheimers disease (AD). Our hypothesis was that cytokeratin 14 (CK14) expression could be used with blood-based biomarkers such as homocysteine, vitamin B12, and folate to identify individuals with MCI or AD from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging. Buccal cells from 54 individuals were analyzed by a newly developed method that is rapid, automated, and quantitative for buccal cell CK14 expression levels. CK14 was negatively ...
Researchers at the University of Glasgows Institute of Health and Wellbeing have announced they have found people with genetic risk of Alzheimers disease exhibiting clear differences in certain biomarkers.. It supports a link between a major genetic risk factor and blood cholesterol levels. The risk factor APOE e4, which is present in a quarter of the population and triples the risk of. dementia, could possibly be the key to future early diagnosis and treatment. The 2% of the. population with a double copy have a 15 times higher risk of developing the disease.. The team investigated associations between common blood biomarkers and apolipoprotein E (APOE), a known genetic risk factor for Alzheimers disease, to improve understanding of disease mechanisms and risk. The study reviewed anonymised data from nearly 400,000 White European participants of the UK Biobank, a public health database, including lifestyle data in their analysis to account for the impact of environmental factors. Using a ...
Hip fracture represents a substantial acute inflammatory trauma, which may constitute a significant insult to the degenerating brain. Research suggests that an injury of this kind can affect memory and thinking in the future but it is unclear whether, and how, inflammatory trauma injures the brain. The impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood BiomarkErs of brain inflammation and injury in Dementia: a study in acute hip fracture patients (ASCRIBED) explores this relationship, to understand the effect of inflammation on the progression of dementia. This protocol describes a multi-centre sample collection observational study. The study utilises the unique opportunity provided by hip fracture operations undertaken via spinal anaesthesia to collect cerebrospinal fluid (CSF) and blood, to investigate the impact of acute brain inflammation caused by hip fracture on the exacerbation of dementia. We will recruit 200 hip fracture patients with a diagnosis or evidence of dementia;
The ARIC (Atherosclerosis Risk in Communities) study recruited a population-based cohort of 15,792 persons between 45 and 64 years of age in 1987-1989, from Forsyth County, NC, and Jackson, MS. In the ARIC study cohort, the investigators measured multiple blood biomarkers of inflammation, hemostasis, thrombin generation, cardiac dysfunction, and vascular stiffness, and identified incident AAAs during follow-up using hospital discharge codes. The authors performed multivariate modeling to obtain hazard ratios of incident clinical AAA in relation to biomarker quartiles by use of Cox proportional hazards regression.. ...
This trial will investigate the effiects of nintedanib [OFEV; Boehringer Ingelheim] on chnages in specific blood biomarkers that can predict course of
The pathogenesis of HIV infection is highly complex and involves numerous actors of the immune system. On the one hand, our immunity has a predominant role in limiting HIV replication and the depletion of its targets, but on the other hand, the persistent infection established by the virus is associated with chronic immune activation and inflammation, potentially resulting in the progressive exhaustion of the host immune resources, and in the onset of non-AIDS-defining comorbidities. The thorough study of HIV pathogenesis is increasingly more challenging. New knowledge together with technological advances offers the possibility to monitor a constellation of cellular immune markers. Here, we discuss the relevance of studying these markers in order to assess the efficacy to control HIV, the inflammatory response to HIV infection, and the alteration and exhaustion of the immune compartments. Monitoring these cellular immune markers is important to reach a deeper understanding of HIV pathogenesis ...
TY - JOUR. T1 - Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimers disease in individuals with subjective cognitive decline (Alzheimers Research & Therapy, (2020), 12, 1, (169), 10.1186/s13195-020-00738-8). T2 - Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimers disease in individuals with subjective cognitive decline (Alzheimers Research & Therapy, (2020), 12, 1, (169), 10.1186/s13195-020-00738-8). AU - Stockmann, Julia. AU - Verberk, Inge M. W.. AU - Timmesfeld, Nina. AU - Denz, Robin. AU - Budde, Brian. AU - Lange-Leifhelm, Julia. AU - Scheltens, Philip. AU - van der Flier, Wiesje M.. AU - Nabers, Andreas. AU - Teunissen, Charlotte E.. AU - Gerwert, Klaus. PY - 2021/12/1. Y1 - 2021/12/1. N2 - Following publication of the original article [1], the authors noticed that the published figures have errors which was occurred during processing of the figures in production team. 1) fonts are shifted ...
In this post-hoc analysis of a subcohort of a large, multicenter prospective cohort study of cardiac surgery patients without creatinine-based acute kidney injury, we did not find evidence of association between either pre- or postoperative biomarker levels and age or sex. However, there were significant differences in biomarker levels associated with urine dipstick findings, including proteinuria, hematuria, leukocyte esterase and nitrites.. All biomarkers were mildly correlated with hematuria, indicating that blood might interfere with biomarker levels or their measurement even in the absence of overt kidney injury evidenced by creatinine rise. Preexisting substances in the urine interfering with assays for novel analytes has been previously described. [10]. We found evidence that proteinuria is associated with all four biomarkers both pre- and post-operatively. Dipstick proteinuria is a marker of preexisting kidney damage and is associated with both the incidence and outcomes of acute kidney ...
Cardiac markers are biomarkers measured to evaluate heart function. They are often discussed in the context of myocardial infarction, but other conditions can lead to an elevation in cardiac marker level. Most of the early markers identified were enzymes, and as a result, the term cardiac enzymes is sometimes used. However, not all of the markers currently used are enzymes. For example, in formal usage, troponin would not be listed as a cardiac enzyme. Measuring cardiac biomarkers can be a step toward making a diagnosis for a condition. Whereas cardiac imaging often confirms a diagnosis, simpler and less expensive cardiac biomarker measurements can advise a physician whether more complicated or invasive procedures are warranted. In many cases medical societies advise doctors to make biomarker measurements an initial testing strategy especially for patients at low risk of cardiac death. Many acute cardiac marker IVD products are targeted at nontraditional markets, e.g., the hospital ER instead ...
The results of this study show that changes in numbers of synovial sublining macrophages correlate with clinical improvement independently of the therapeutic strategy. Furthermore, this study demonstrates that the change in the numbers of sublining macrophages may be used to explain clinical outcome. Of importance, the data indicate that the change in the number of sublining macrophages could be used as a sensitive biomarker to predict possible efficacy of a new antirheumatic treatment.. Previous work suggested an association between the number of synovial macrophages and joint destruction in RA.14 Moreover, analysis of the synovial cell infiltrate demonstrated a positive correlation between scores for local disease activity and the number of macrophages as well as expression of macrophage derived cytokines (tumour necrosis factor α (TNFα) and interleukin (IL) 6) in rheumatoid ST, suggesting that macrophage numbers are associated with clinical signs of inflammation.2 In keeping with this ...
SirYus technology enables sensitive and reproducible tests for cancer screening by combining several biomarkers to establish an appropriate diagnosis.. Considerable efforts have been devoted to search specific markers with relatiely few results. In fact, from 1261 proteins identified as potentially discriminatory in human cancers, only nine have received final approval from the FDA as biomarkers of tumors.. Many opinion leaders now believe that the pursuit of individual biomarkers will be vain, and that several biomarkers are needed to properly identify cancers in screening protocols.. SirYus multiplex technology brings new solutions to this complex challenge. Simultaneous testings of several biomarkers can largely improve screening sensitivity and specificity.. ...
In clinical practice, biomarkers can be used to identify risk and susceptibility, diagnose a disease, assess disease severity or progression, classify patients, guide treatment, and predict prognosis. In drug development and the pharmaceutical industry, biomarkers can be used to predict toxicity, safety, or efficacy of a drug. Biomarkers can be categorized as target, mechanism and clinical to indicate if a drug hits its intended target, alters any mechanisms and if it is effective in vivo. Biomarkers can be also classified into three types: type 0 - natural history markers, type 1 - biological or drug activity markers, and type 2 - surrogate markers. Type 0 biomarkers measure the natural history of a disease and should correlate over time with known clinical indicators. They can be characterized in phase 0 clinical trials. Symptoms over the full range of a disease and most prognosis markers are type 0 biomarkers. In most cases, type 1 biomarkers are the markers that capture the effects of a ...
With demographic shifts toward older populations, the number of people with dementia is steadily increasing. Alzheimers disease (AD) is the most common cause of dementia, and no curative treatment is available. The current best strategy is to delay disease progression and to practice early intervention to reduce the number of patients that ultimately develop AD. Therefore, promising novel biomarkers for early diagnosis are urgently required. To identify blood-based biomarkers for early diagnosis of AD, we performed RNA sequencing (RNA-seq) analysis of 610 blood samples, representing 271 patients with AD, 91 cognitively normal (CN) adults, and 248 subjects with mild cognitive impairment (MCI). We first estimated cell-type proportions among AD, MCI, and CN samples from the bulk RNA-seq data using CIBERSORT and then examined the differentially expressed genes (DEGs) between AD and CN samples. To gain further insight into the biological functions of the DEGs, we performed gene set enrichment analysis (GSEA
CSDE is offering a hands-on workshop in biomarker methods that provide quick on-site measurements in non-clinical settings without the need to transport samples back to a lab. Well practice proper technique for minimally invasive measures like height, weight, body composition, and blood pressure, and the use of simple tools for biomarker testing with blood collected from a finger prick. A brief lecture component will cover costs, logistics, human subjects implications, and strengths and limitations of this approach to biomarker data collection. Please email Ellie Brindle ([email protected]) to register.. ...
Attempts to find a lone biomarker for Alzheimers disease - whether its in blood, spinal fluid, or the brain - have largely failed. The Texas Alzheimers Research Consortium project conducted a longitudinal case-control study, using stored blood samples to develop an algorithm that separates patients with Alzheimers disease from controls. The biomarker assays looked at hundreds of proteins, including thrombopoietin, TNF-alpha, creatine kinase, and various interleukins. The his team focused on a large array of blood-based proteins, since assay technology has now made it possible to evaluate large amounts of data. Screening for these biomarkers and factoring in age, sex, education, and APOE status led to a sensitivity of 0.94 and a specificity of 0.84, as reported by Sid OBryant, PhD, of Texas Tech University, in Lubbock, Texas, and colleagues in the Archives of Neurology. They also saw that many of the proteins with the highest importance were inflammatory in nature, which suggests that the ...
Background: Metabolic alterations correlate with adverse outcomes in type 2 diabetes. Dietary modification serves as an integral part in its treatment.. Objective: We examined the relationships among dietary patterns, dietary biomarkers, and metabolic indicators in type 2 diabetes (n = 871).. Design: Diabetic patients (n = 871) who provided complete clinical and dietary data in both 2008 and 2009 were selected from a cohort participating in a diabetic control study in Taiwan. Dietary data were obtained using a short, semiquantitative food frequency questionnaires, and dietary pattern identified by factor analysis. Multiple linear regressions were used to analyze the association between dietary biomarkers (ferritin, folate, and erythrocyte n-3 polyunsaturated fatty acids [n-3 PUFAs]) and metabolic control upon adjusting for confounders.. Results: Three dietary patterns (high-fat meat, traditional Chinese food-snack, and fish-vegetable) were identified. Ferritin correlated positively with high-fat ...
In this study, biomarker response after supplementation with oral and intramuscular vitamin B12 will be compared in a randomized clinical trial. Electronic compliance monitoring will be used to control for non compliance as a possible confounder in oral treatment. Additionally subjective acceptance in terms of presumed preferences will be compared with oral vs. intramuscular supplementation of vitamin B12 in the view of the patient ...
A diagnostic study of 136 premature infants found that a protein involved in managing harmful bacteria in the human intestine is a reliable biomarker for the noninvasive detection of necrotizing enterocolitis.
Purdue University researchers have found a method of identifying biological markers in small amounts of blood that they believe could be used to detect a myriad of diseases, infections and different medical conditions at early stages.
Hypothesis: The association of excess weight with an adverse cardiometabolic profile in patients with type 1 diabetes (T1D) is unclear. The purpose of this study was to test the hypothesis that increasing BMI and adiposity indicators in youth with T1D are adversely associated with glycemic control and cardiovascular biomarkers.. Methods: Subjects were youth participants of a family-based randomized controlled dietary intervention (N=136, age=12.3±2.5y, baseline A1c=8.1±1.1%). Glycemic control (A1c and 1,5-Anhydroglucitol, 1,5-Ag), body mass index (BMI, from measured height and weight), serum lipids (total cholesterol, TC; HDL-cholesterol, HDL-C; LDL-cholesterol, LDL-C; triglycerides, TG), inflammation (c-reactive protein, CRP), oxidative stress (8-iso-prostaglandin F2alpha, 8-iso-PGF2α), adiponectin and blood pressure (systolic, SBP; diastolic, DBP) were assessed at baseline and every 6 months for 18 months. Total and truncal lean, fat-free mass and percent fat (%fat) were measured by Dual ...
Nivolumab response rate is 40% in metastatic melanoma. Few studies have evaluated pre-treatment biomarkers predictive of response. The aim of this study was to identify potential peripheral blood biomarkers associated with survival in patients with advanced melanoma treated with nivolumab. All advanced melanoma cases treated with anti-programmed cell death protein 1 (anti-PD1) over a 3-year period in our department were identified. For each case, 9 potential blood biomarkers were identified. Bivariate and multivariate analyses, adjusted for the American Joint Committee on Cancer (AJCC) classification stage, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase (LDH) level and failure to respond to first-line therapy, were used to test the association between biomarkers and overall survival (primary outcome) or progression-free survival (secondary outcome ...
Using machine learning tools to analyze hundreds of proteins, UT Southwestern researchers have identified a group of biomarkers in blood that could lead to an earlier diagnosis of children with autism spectrum disorder (ASD) and, in turn, more effective therapies sooner.
Biomarkers in the bloodstream could provide a rapid assessment of therapeutic intervention in ischemic stroke and allow patient stratification Researc
Treatment-emergent depression is a common complication in patients with chronic hepatitis C virus (HCV) infection undergoing antiviral combination therapy
Non-invasive biomarkers in NASH are beginning to show where and how they can upstage liver biopsies, with the first impact appearing in patient recruitment.
ESMO) 2016 Congress. The presentation included interim efficacy and safety outcomes, as well as initial findings from the companys ongoing biomarker analysis of samples collected during the study. The SUNRISE Phase III trial was discontinued earlier this year based on a pre-specified interim analysis although patient treatment and follow-up in the study were allowed to continue. The pre-planned biomarker analysis has been taking place as patient follow-up has continued and available results were evaluated as part of the recent top-line data analysis. The study protocol pre-specified the collection of thousands of patient samples for exploratory analyses over a wide range of possible biomarkers, including pre-treatment levels of beta-2 glycoprotein-1 (β2GP1). Data presented at ESMO demonstrated that patients with pre-treatment β2GP1 levels between 200 and 240 (representing approximately 30% of randomized patients) achieved a statistically significant, 5.5-month improvement (13.2 months vs. 7.7 ...
Our literature search identified 93 studies evaluating an overall of 70 different blood markers for CRC, including long discussed ones like carcinoembryonic antigen and carbohydrate antigens, as well as newly introduced ones like proteins identified through MS analysis. A broad timeframe with first studies from 1979 (75) to 2006 (49, 73, 74, 77, 81, 89-91, 102) was covered. The majority of studies evaluated protein markers, but in recent years, an interesting number of studies also evaluated genetic and epigenetic markers.. Overall, a broad range of sensitivity and specificity was reported for the various markers. A direct comparison of results from different studies is complicated due to the diverse populations used (different age, origin, normal, or diseased controls), the diverse number of markers evaluated (single versus combined markers) and use of different cutoff points for the same marker (M2-PK and CEA). Furthermore, the majority of markers were evaluated in only one study, especially ...
Eglinton, Geoffrey (2004): Lipid biomarkers at station CD47_0206S#16. PANGAEA, https://doi.org/10.1594/PANGAEA.206180, In: Lowry, Roy K; Machin, P (2016): Compilation of the results of EU-project BOFS. PANGAEA, https://doi.org/10.1594/PANGAEA.859221
Alzheimer disease biomarker testing in cerebrospinal fluid : a method to harmonize assay platforms in the absence of an absolute reference standard ...
Researchers with eyes peeled toward prodromal Alzheimers disease probably see this diagram in their sleep-the one where the fields five most validated markers trace their poignant path from normal cognition to fully developed AD. Two research groups proposed this theoretical model some years ago (see Perrin et al., 2009; Jack et al., 2010). But is it true? At least in its broad strokes, the answer seems to be yes, according to early data pouring in from biomarker studies in autosomal-dominant AD. By and large, brain amyloid, brain metabolism, atrophy, and functional connectivity data from independent analyses of the Dominantly Inherited Alzheimer Network (DIAN) and the Alzheimers Prevention Initiative (API) jibe with each other and confirm the sequence of preclinical biomarker changes proposed for late-onset AD. This article highlights DIAN and API neuroimaging results reported 14-19 July 2012 at the Alzheimers Association International Conference (AAIC) in Vancouver, Canada.. DIAN and API ...
Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases earlier and assess disease activity more accurately. These markers have been incorporated into the recently revised classification criteria of several diseases to enable early diagnosis and timely initiation of treatment. Furthermore, they also facilitate more accurate subclassification and more focused monitoring for the detection of certain disease manifestations, such as lung and renal involvement. These biomarkers can also make the assessment of disease activity and treatment response more reliable. Simultaneously, several new serological and proteomic biomarkers have become available in the routine clinical setting-for example, a protein biomarker panel for rheumatoid arthritis and a myositis antibody panel for dermatomyositis and polymyositis. This review will focus on commercially available antibody and proteomic biomarkers in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis ...
Serum cytokeratin-18 is a non-invasive biomarker for evaluating disease severity in patients with liver cirrhosis and hepatocellular carcinoma
Semantic Scholar extracted view of Dynamic changes in calprotectin and its correlation with traditional markers of oxidative stress in patients with acute ischemic stroke. by Antonios Chatzopoulos et al.
Biomarker classification depends on its context of use, which in turn defines the extent to which the biomarker must be validated. In terms of requirements for validation, the holy grail of biomarker application is one that can serve as a surrogate endpoint in a clinical trial. A surrogate endpoint is a laboratory (or physical) measurement that is used in a clinical trial as a substitute for a clinical endpoint (e.g., survival or functional endpoint). Therefore, a surrogate endpoint must accurately predict the effect of therapeutic intervention. Guidance for Industry: Pharmacogenomic Data Submissions. The use of companion diagnostics to drive molecularly targeted drug development also requires that the diagnostic be clinically validated through the FDAs PMA or 510(K) process. In both of these instances the biomarker must be analytically validated (inclusive of the test platform, reagents, etc.).. The subtle differences between biomarkers, diagnostics, surrogate endpoints and companion ...
This study has been designed to evaluate a new oral test for therapeutic monitoring of HIV/AIDS patients that are receiving the combination Anti-Retroviral Therapy (cART). The test will measure saliva-based Stress Response Profiling(SRP) biomarkers using laboratory assays. Results of the test will show if HIV/AIDS patients successfully responded to cART. Preliminary studies showed that SRP biomarkers were strongly increased in cART-unresponsive AIDS patients. However, the diagnostic accuracy of the oral test, patients will be recruited to donate saliva: AIDS patients responsive or unresponsive to cART, and controls (acute or early HIV patients, and HIV-negative patients with hepatitis).. The saliva samples will be used to measure SRP biomarker concentrations. Results will show whether the biomarker measurements provide accurate and specific diagnostics for ART response. ...
Below is a brief summary of dates of CSF biomarker analyses run as batches of samples using the Luminex xMAP platform and Innogenetics INNO-BIA AlzBio3? immunoassay reagents. Normalization of CSF biomarker data between results of 2007 and 2008 have been obtained using a statistical approach, resulting in a procedure to maintain lot-to-lot consistency within clinical studies. In addition, during the further review of the pTau181p data a subset of CSF samples required quaranteening all pTau181p data from the late 2008 batch run. The normalization applies to all t-tau, A?1-42 and pTau181p results, with the exception of the subset of pTau181p results that require a special correction procedure that is in the process of being completed. That specific subset of data will be uploaded in the near future.. Batch runs of ADNI CSF samples ...
This paper addresses the problem of classifying cells expressing different biomarkers. A deep learning based method that can automatically localize and count the cells expressing each of the different biomarkers is proposed. To classify the cells, a Convolutional Neural Network (CNN) was employed. Images of Immunohistochemistry (IHC) stained slides that contain these cells were digitally scanned. The images were taken from digital scans of IHC stained cervical tissues, acquired for a clinical trial. More than 4,500 RGB images of cells were used to train the CNN. To evaluate our method, the cells were first manually labeled based on the expressing biomarkers. Then we performed the classification on 156 randomly selected images of cells that were not used in training the CNN. The accuracy of the classification was 92% in this preliminary data set. The results have shown that this method has a good potential in developing an automatic method for immunohistochemical analysis ...
Fingerprint Dive into the research topics of Level of dietary energy and 2,4-thiazolidinedione alter molecular and systemic biomarkers of inflammation and liver function in Holstein cows. Together they form a unique fingerprint. ...
Normally distributed continuous variables were compared with the Student t test and skewed-distributed with the Wilcoxon rank-sum test. Categorical variables were compared with the chi-square test. The prognostic value of the biomarkers was assessed by investigating the relationship between mortality and biomarkers in 2 sets of Cox proportional-hazards analyses: univariate analyses of single biomarkers and multivariate analysis including all biomarkers (multimarker). The univariate analyses were used to determine cutoff values for the biomarkers. These cutoff values were based on the quartiles of the individual biomarker levels. When hazard did not differ significantly between adjacent quartiles, as indicated by the p value from the Cox model, these were merged.. A multivariate model initially was developed incorporating the 5 biomarkers. Biomarkers with p < 0.05 by the Wald test were identified by backward selection. From the final model, a simplified score was obtained by putting weights to ...
Learn about the veterinary topic of Other Serum Biochemical Measures in Hepatic Disease in Small Animals. Find specific details on this topic and related topics from the Merck Vet Manual.
Press Release issued Jul 8, 2014: Biomarkers also known as biological markers are characteristics that are measured in order to assess and predict biological condition of the body and thus help physicians in clinical decision making. Some major diseases which are diagnosed by using biomarkers include diabetes, cancer and cardiovascular and central nervous system diseases. Biomarkers play critical role in identifying and accurate diagnosis of these diseases at early stage and provide better treatment option. Imaging biomarkers can be classified as diagnostic biomarkers, monitoring biomarkers and predictive biomarkers. Diagnostic biomarkers are helpful in predicting a patients exact clinical outcome. Monitoring biomarkers provides clinical outcome of a patient after intake of a particular drug while predictive biomarkers help in predicting if a specific drug is likely to change clinical outcome of a patient.
The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for therapy. Strategies have been pursued to inhibit neovascularization and to destroy existing tumor vessels, or both. These include direct targeting of endothelial cells, and indirect targeting by inhibiting the release of proangiogenic growth factors by cancer or stromal cells. Many patients benefit from antiangiogenic therapies; thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in their management. A number of non-invasive tools are described with their potential benefits and limitations. We review currently available candidate biomarkers of anti-angiogenic agent effect. Including these markers into clinical trials may provide insight into appropriate dosing for desired biological effects, appropriate timing of additional therapy, and prediction of individual response. This has important consequences for the clinical use of angiogenesis
The objective of the project is to validate a serum biomarker signature for the early diagnosis (yes/no diagnosis) of pancreatic cancer...
The Applied Biosystems TaqMan Advanced Serum/Plasma 96-Well Plates, Standard, provide the convenience of pre-spotted TaqMan Advanced miRNA assays in a 96-well standard plate format. This product contains a set of 2 plates for profiling of up to 188 unique miRNAs in serum/plasma samples, and includes
In [11], we first proposed an efficient algorithm, AMFES (Adaptive Multiple FEatues Selection), to select important biomarkers for cancers. Based on that initial success, this paper reports the extension of previous results on the datasets provided by Maes et al. in an attempt to discover important biomarkers for AD from the blood-based samples [12]. Unlike traditional statistical analyses, AMFES is an SVM-based methodology, which can select a much smaller subset of important biomarkers. In addition, AMFES applies an adaptive method which enables selection of a globally optimal subset of important biomarkers compared to SVM-RFE. AMFES is particularly useful for differentiating noisy biomarkers from the relevant ones when interferences between biomarkers exist. Our results are supported by a high ROC/AUC (Receiver Operating Characteristic/Area Under Curve) value when we apply a cross-validation verification. Thus, AMFES should play an important role in the classification framework of ...
Press Release issued Apr 25, 2014: Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia. The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis.
VOLUNTARY PROVISION OF INFORMATION ON BIOMARKERS AND INTERMEDIATEENDPOINTS IN PREVENTION TRIALS NIH GUIDE, Volume 23, Number 12, March 25, 1994 P.T. Keywords: National Cancer Institute The National Cancer Institute (NCI) announces the establishment of a biomarker registry comprised of information that may be useful to investigators when biomarkers are being considered as intermediate endpoints or as outcome measures in prevention trials. In an effort to collect information on biomarkers, the NCI seeks cooperation from the extramural scientific community on a voluntary basis. Information may be submitted by anyone currently engaged in biomarker research. The following characteristics of biomarkers are of interest: 1. Biological Characteristics: The description should include, but is not limited to, the spontaneous biological rate of progression and/or regression, site-specificity, histology, chromosomal aberrations, epigenetic changes, mutations, histologic correlation, and the phase, i.e., ...
BACKGROUND: In patients with end-stage renal disease (ESRD), the ability of single and multiple biomarker monitoring to predict adverse outcomes has not been well established. This study determined the prognostic value of multiple biomarkers for all-cause death over 2 years in 399 ESRD patients.. METHODS: The risk of all-cause death was determined by use of multiple biomarkers based on concentrations for a reference population (normal) and cutoffs based on tertile distributions in the ESRD group. Biomarkers studied included N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP; Dade Behring and Roche assays), and cardiac troponin T (cTnT; Roche) and I (cTnI; Dade Behring and Beckman Coulter assays). Relative risks of death were estimated and survival curves computed.. RESULTS: A total of 101 deaths occurred during 594 patient-years of follow-up. Increased NT-proBNP concentrations were not predictive of death on the basis of the normal cutoffs. However, ...
Background Linifanib is a potent and selective VEGF and PDGF receptor inhibitor that has activity in unselected, advanced NSCLC patients (pts) both as monotherapy in the relapsed setting and with carboplatin (C) and paclitaxel (P) in the first-line setting. A baseline plasma biomarker signature identifying NSCLC pts most sensitive to linifanib is needed.. Methods An exploratory retrospective analysis of 4 randomized clinical trials (linifanib or other treatments: ABT-510 [thrombospondin mimetic], pemetrexed +/- ABT-751 [tubulin inhibitor], docetaxel +/- ABT-751) in relapsed NSCLC was conducted. Evaluable baseline plasma samples were obtained from 116 pts who received linifanib and 125 pts on other treatments. A signature combining established tumor markers (carcinoembryonic antigen [CEA] and fragments of cytokeratin 19 [CYFRA 21-1]) was derived using a sequential BATTing approach. The signature was then tested across a randomized trial of CP + placebo, linifanib 7.5 mg, or linifanib 12.5 mg in ...
1 Industry Overview. 1.1 Definition and Specifications of Molecular Biomarkers for Cancer Detection and Management. 1.2 Classification of Molecular Biomarkers for Cancer Detection and Management. 1.3 Applications of Molecular Biomarkers for Cancer Detection and Management. 1.4 Industry Chain Structure of Molecular Biomarkers for Cancer Detection and Management. 1.5 Industry Overview and Major Regions Status of Molecular Biomarkers for Cancer Detection and Management. 1.5.2 Global Major Regions Status of Molecular Biomarkers for Cancer Detection and Management. 1.6 Industry Policy Analysis of Molecular Biomarkers for Cancer Detection and Management. 1.7 Industry News Analysis of Molecular Biomarkers for Cancer Detection and Management. 2 Manufacturing Cost Structure Analysis of Molecular Biomarkers for Cancer Detection and Management. 2.1 Raw Material Suppliers and Price Analysis of Molecular Biomarkers for Cancer Detection and Management. 2.2 Equipment Suppliers and Price Analysis of Molecular ...
Our data indicate first that among a panel of 10 biomarkers, plasma Nt-proBNP level predicts future fatal and nonfatal cardiac events and adds significantly to the information obtained from determination of traditional risk factors in individuals with existing CVD. Second, although various inflammatory biomarkers and microalbuminuria were individually significantly related to future cardiovascular risk, they added very little additional prognostic information to the traditional markers. Third, the present data illustrate that models that include simple and readily available risk factors do not gain accuracy by the inclusion of any inflammatory biomarker for prediction of cardiovascular events in this setting of preexisting disease.. An increasing number of biomarkers have been proposed to identify patients at high risk for future cardiovascular events in the setting of primary3-6,19 and secondary7-9,20 prevention, as well as acute coronary syndrome.10,21-25 From a clinical perspective, the ...
TY - JOUR. T1 - Clinical utility of NT-proBNP, a new biomarker of cardiac function and heart failure. AU - Ishii, Junichi. PY - 2008/4. Y1 - 2008/4. N2 - Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP), a new biomarker of cardiac function and heart failure, has become available as a clinical laboratory test in Japan. Its diagnostic and prognostic utility appears to be equivalent to BNP in the clinical setting; however, there are some biologic differences between NT-proBNP and BNP. Unlike BNP, NT-proBNP is not degraded in the circulation, and is stable even in serum. It has a longer half-life of approximately 1 to 2 hours, leading to higher circulating levels and slower fluctuations than BNP. Both of these biomarkers are influenced by renal function, but the effect is greater for NT-proBNP. Recently, NT-proBNP has become an important diagnostic tool for assessing patients who present acutely with dyspnea, and provides important prognostic information in both acute and chronic ...
Urine samples were collected between 2002 and 2006 among 287 pregnant women from Eden and Pélagie cohorts, from which phthalates and phenols metabolites levels were assayed. We applied a 2-step standardization method based on regression residuals. First, the influence of sampling conditions (including sampling hour, duration of storage before freezing) and of creatinine levels on biomarker concentrations were characterized using adjusted linear regression models. In the second step, the model estimates were used to remove the variability in biomarker concentrations due to sampling conditions and to standardize concentrations as if all samples had been collected under the same conditions (e.g., same hour of urine collection ...
TY - JOUR. T1 - Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimers disease. AU - Palmqvist, Sebastian. AU - Insel, Philip S.. AU - Stomrud, Erik. AU - Janelidze, Shorena. AU - Zetterberg, Henrik. AU - Brix, Britta. AU - Eichenlaub, Udo. AU - Dage, Jeffrey L.. AU - Chai, Xiyun. AU - Blennow, Kaj. AU - Mattsson, Niklas. AU - Hansson, Oskar. PY - 2019/12/1. Y1 - 2019/12/1. N2 - Failures in Alzheimers disease (AD) drug trials highlight the need to further explore disease mechanisms and alterations of biomarkers during the development of AD. Using cross-sectional data from 377 participants in the BioFINDER study, we examined seven cerebrospinal fluid (CSF) and six plasma biomarkers in relation to β-amyloid (Aβ) PET uptake to understand their evolution during AD. In CSF, Aβ42 changed first, closely followed by Aβ42/Aβ40, phosphorylated-tau (P-tau), and total-tau (T-tau). CSF neurogranin, YKL-40, and neurofilament light increased after the ...
Different classes of cardiovascular biomarkers are thought to provide information concerning different pathophysiological mechanisms.16 Because anthracycline therapy is associated with both cardiomyocyte injury, loss of cardiac contractile function, inflammation, and development of diffuse fibrosis,17 we selected biomarkers that are believed to reflect these processes in our study.. Cardiac troponins are markers of cardiomyocyte injury and are associated with risk for cardiovascular death and heart failure.18 Moreover, the use of high‐sensitivity assays for cTnI and cTnT also permits detection and monitoring of low‐grade, chronic myocardial injury.19 BNP and NT‐proBNP are associated with cardiac function and provide strong prognostic information across the spectrum of cardiovascular disease.20, 21, 22 CRP is a prototypical inflammatory biomarker that has been associated with the incidence of cardiovascular disease and death, both in the general population, in patients with coronary artery ...
The high sensitivity C-reactive protein (hs-CRP), mediator of atherosclerotic disease, is known to be a sensitive predictor of coronary heart disease in type 2 diabetes mellitus (T2DM).. Aims: To evaluate the relationship of hs-CRP levels to metabolic syndrome (MS) and albuminuria in T2DM.. Methods: Four hundred and eighty-eight T2DM subjects were recruited. Patients with hs-CRP ≥10 mg/l, creatinine ≥1.4 mg/dl, chronic inflammatory and cardiovascular diseases, smokers or on antiplatelet therapy were excluded. In all the 178 subjects (65.2±10.7 years, 71 men and 107 women) enrolled, we measured hs-CRP, waist circumference (WC), fasting plasma glucose (FPG), systolic and diastolic blood pressure, high density lipoprotein-cholesterol (HDL-Ch), triglycerides (TGs), and 24 h. Albumin excretion (ALB-e). The MS was defined according to the IDF criteria. Student s t-test was used to compare the means, and the Mann Whitney U test to analyze the relationship between hs-CRP levels and the presence of ...
Our Canary Club High Sensitivity C-Reactive Protein (hs-CRP) blood-spot test provides an accurate assessment of the amount of inflammation in the body to provide physicians with more diagnostic clues regarding a persons cardio metabolic risk.. People who have hs-CRP levels in the high end of the normal range have a 1.5 to 4 times greater risk of having a heart attack as those in the low end of the normal range.. Measurement of hs-CRP does not reflect where in the body the inflammation is, however. It may reflect inflammation detected in cells in the fatty deposits of arterial walls, or it may reflect inflammation from any part of the body. However, when hs-CRP is tested in combination with other cardio metabolic markers, physicians can find valuable clues regarding a persons risk for type 2 diabetes, heart attack, and stroke.. Symptoms of irregular hs-CRP levels:. ...
TY - JOUR. T1 - Relation of Soft Plaque and Elevated Preprocedural High-Sensitivity C-Reactive Protein Levels to Incidence of In-Stent Restenosis After Successful Coronary Artery Stenting. AU - Hong, Young Joon. AU - Jeong, Myung Ho. AU - Lim, Sang Yeob. AU - Lee, Sang Rok. AU - Hong, Seo Na. AU - Kim, Kye Hun. AU - Sohn, Il Suk. AU - Park, Hyung Wook. AU - Kim, Ju Han. AU - Kim, Weon. AU - Ahn, Youngkeun. AU - Cho, Jeong Gwan. AU - Park, Jong Chun. AU - Kang, Jung Chaee. PY - 2006/8/1. Y1 - 2006/8/1. N2 - Although various predictors relating to in-stent restenosis (ISR) have been demonstrated, the relation between the parameters of intravascular ultrasound and inflammatory markers and ISR has not been reported. This study included 120 patients who underwent stent implantation for angiographically significant stenosis. Patients were divided into a soft plaque group (n = 50) and a nonsoft plaque group (n = 70). All patients underwent angiographic and intravascular ultrasound follow-up at 6 ...
TY - JOUR. T1 - Progress of research in osteoarthritis. The evaluation of osteoarthritis with biological markers. AU - Morita, Mitsuhiro. AU - Yamada, Harumoto. AU - Date, Hideki. AU - Yoshimura, Noriko. PY - 2009/11. Y1 - 2009/11. N2 - It is socially required to establish the correlation of some specific biomarkers and the clinical stage of osteoarthritis (OA). This study is to evaluate the usefulness of serum or urine biomarkers in OA in the large population cohort study of Japan. There are many reports to evaluate the usefulness of biological markers in OA, and the similar clinical results are supported in this study. The further follow-up study would be wished to be done.. AB - It is socially required to establish the correlation of some specific biomarkers and the clinical stage of osteoarthritis (OA). This study is to evaluate the usefulness of serum or urine biomarkers in OA in the large population cohort study of Japan. There are many reports to evaluate the usefulness of biological ...
1] Foerch C., Montaner J., Furie K.L., Ning M.M. and Lo E.H., Invited Article: Searching for oracles? Blood biomarkers in acute stroke, Neurology 73(5), 393-399 (2009). [2] Whiteley W., Tseng M.C. and Sandercock P., Blood biomarkers in the diagnosis of ischemic stroke: a systematic review, Stroke 39(10), 2902-2909 (2008). [3] Whiteley W., Chong W.L., Sengupta A. and Sandercock P., Blood markers for the prognosis of ischemic stroke: a systematic review, Stroke 40(5), 380-389 (2009). [4] Carlborg C. F., Gylfason K. B., Kaźmierczak A., Dortu F., Banuls M. J., Kresbach G. M., Sohlström H., Moh T., Vivien L., Popplewell J., Ronan G., Barrios C.A., Stemme G. and van der Wijngaart W., A packaged optical slot-waveguide ring resonator sensor array for multiplex assays in labs-on-chip, Lab on Chip 10 , 281- 290 (2010). [5] Sinclair W., Schmid J.H., Waldron P., Poitras D., Janz S., Mischki T., Lopinski G., Densmore A., Xu D.-X., Lapointe J. and Delâge A., Silicon photonic evanescent field ...
Background: Plaque rupture, acute ischemia, and necrosis in acute coronary syndromes are accompanied by concurrent pro-and anti-inflammatory cascades. Whether STEMI clinical prediction models can be improved with the addition of baseline inflammatory biomarkers remains unknown. Methods: In an APEX-AMI trial substudy, 772 patients had a panel of 9 inflammatory serum biomarkers, high sensitivity C reactive protein (hsCRP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured at baseline after randomization. Baseline biomarkers were incorporated into a clinical prediction model for a composite of 90-day death, shock, or heart failure. Incremental prognostic value was assessed using Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI). Results: Individually, several biomarkers were independent predictors of clinical outcome: hsCRP (hazard ratio [HR] 1.12; 95% confidence interval [CI], 1.03-1.21; p=0.007, per doubling), NT-proBNP (HR 1.14; 95% CI, ...
Diabetic kidney disease is the leading cause of end-stage renal disease in developed and developing countries. Microalbuminuria is the gold standard for detection and prediction of diabetic kidney disease and cardiovascular risk disease in clinical practice. However, microalbuminuria has several limitations, such as lower sensitive, larger variability. It is urgent to explore higher sensitivity and specificity for earlier detection of diabetic kidney disease and more accurate prediction of the progression to end stage renal disease. We reviewed some new and important urinary biomarkers, such as: transferrin, immunoglobulin G, immunoglobulin M, Cystanic C, podocytes, type IV collagen, 8-oxo-7, 8-dihydro-2-deoxyguanosine, ceruloplasmin, monocyte chemoattractant protein-1 and so on. We need good quality, long-term, large longitudinal trials to validate published biomarkers and find new biomarkers, considering biomarkers reviewed here are from small cross-sectional studies.
Amyotrophic lateral sclerosis (ALS) is a highly progressive and debilitating neurodegenerative disease, which usually leads to the death of affected individuals within a few years after the onset of symptoms. ALS is currently incurable and very little is known about its pathophysiology. Finding validated biomarkers will help us to advance our understanding of ALS etiology and find better strategies for early diagnosis and management of the disease. The main aim of the present systematic review is to evaluate the concentration of 11 frequently reported biomarkers for ALS in peripheral blood and CSF of patients diagnosed with ALS compared with controls. This systematic review protocol has been established according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) 2015 guideline. We will include all types of observational studies with human subjects that investigated the concentrations of intended biomarkers (amyloid beta (Aβ-42), tau and phosphorylated tau (p
Purdue University researchers have found a method of identifying biological markers in small amounts of blood that they believe could be used to detect a myriad of diseases, infections and different medical conditions at early stages.. Jeffrey Rhoads, a professor in Purdues School of Mechanical Engineering; George Chiu, a professor in Purdues School of Mechanical Engineering, School of Electrical and Computer Engineering, and Department of Psychological Sciences; and Eric Nauman, a professor in the School of Mechanical Engineering, Department of Basic Medical Sciences and the Weldon School of Biomedical Engineering, are part of a team of researchers that has created microelectromechanical resonators, or small vibrating sensors, that can detect these biomarkers using just a drop or two of blood. The plate-style resonant sensors allows sensitive, inexpensive detection of biomarkers that can signify disease, illness or trauma.. The goal here is to find the disease so early that you can treat it ...
Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system. Only a few biomarkers are available in MS clinical practice, such as cerebrospinal fluid oligoclonal band
BLOOD MARKER FOR RENAL CANCER - The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer ...
Even though the post-operative outcome varies greatly among patients with nodal positive colon cancer (UICC stage III), personalized prediction of systemic disease recurrence is currently insufficient. We investigated in a retrospective setting whether genetic and immunological biomarkers can be applied for stratification of distant metastasis occurrence risk. Eighty four patients with complete resection (R0) of stage III colon cancer from two clinical centres were analysed for genetic biomarkers: microsatellite instability, oncogenic mutations in KRAS exon2 and BRAF exon15, expression of osteopontin and the metastasis-associated genes SASH1 and MACC1. Tumor-infiltrating CD3 and CD8 positive T-cells were quantified by immunocytochemistry. Results were correlated with outcome and response to 5-FU based adjuvant chemotherapy, using Coxs proportional hazard models and integrative two-step cluster analysis. Distant metastasis risk was significantly correlated with oncogenic KRAS mutations (p = 0.015),
We previously showed that IDH1 mRNA and protein expression are elevated in tumor tissues compared with matched normal tissues (10). This suggests that IDH1 plasma level might be a useful biomarker for the diagnosis of patients with NSCLCs. We have 2 hypotheses for the elevated levels of IDH1 in blood, which are currently being investigated: IDH1 may be secreted extracellularly under exceptional circumstances or released into the blood by cell damage and cell death. In addition, plasma IDH1 levels were positively correlated with T stage in patients with NSCLCs, strongly suggesting that IDH1 might be a useful diagnostic biomarker.. In this report, we showed that the plasma IDH1 level was significantly elevated in 976 patients with NSCLCs compared with 479 healthy controls. We also tested 3 existing clinical biomarkers, CEA, CA125, and Cyfra21-1, in all the samples and compared their diagnostic efficacy to that of IDH1. Then, we established the AUCs for biomarker panels and determined the ...
We are excited to present the first of our 2021 webinar series. Dr Robert Mohney, Head of Clinical and Translational Science at Owlstone Medical, will be presenting Discovery and Clinical Investigation of Non-Invasive Biomarkers using Breath Biopsy® at 1pm EST / 10am PST on January 27th.. Dr Mohney will introduce a series of case studies, showcasing the applications of breath analysis and the potential for its use in clinical practice. This webinar is for anyone interested in learning about Breath Biopsy and its capabilities for early detection of disease and precision medicine. The presentation will be followed by a live Q&A session.. Watch On Demand. Contact us. ...
IBBL recently supported the Department of Oncology (DONC) of the Luxembourg Institute of Health in advancing lung cancer diagnostics.
Mediators of Inflammation is a peer-reviewed, Open Access journal that publishes original research and review articles on all types of inflammatory mediators, including cytokines, histamine, bradykinin, prostaglandins, leukotrienes, PAF, biological response modifiers and the family of cell adhesion-promoting molecules.
Background: The relationship between age-related frailty and the underlying processes that drive changes in health is currently unclear. Considered individually, most blood biomarkers show only weak relationships with frailty and ageing. Here, we examined whether a biomarker-based frailty index (FI-B) allowed examination of their collective effect in predicting mortality compared with individual biomarkers, a clinical deficits frailty index (FI-CD), and the Fried frailty phenotype.Methods: We analyzed baseline data and up to 7-year mortality in the Newcastle 85+ Study (n = 845; mean age 85.5). The FI-B combined 40 biomarkers of cellular ageing, inflammation, haematology, and immunosenescence. The Kaplan-Meier estimator was used to stratify participants into FI-B risk strata. Stability of the risk estimates for the FI-B was assessed using iterative, random subsampling of the 40 FI-B items. Predictive validity was tested using Cox proportional hazards analysis and discriminative ability by the ...
Plasma microRNAs (miRNAs) are promising non-invasive biomarkers for colorectal cancer (CRC) prognosis. However, the published studies to date have yielded conflicting and inconsistent results for specific plasma miRNAs.. We have conducted a study using robust assays to assess a panel of nine miRNAs for CRC prognosis and early detection of recurrence. Plasma samples from 144 patients in a prospective CRC cohort study were collected at diagnosis, 6, 12, and 24 months after diagnosis. miRNAs were assayed by Taqman qRT-PCR to generate miRNA normalised copy numbers.. Preoperative high plasma miRNA levels were associated with increased recurrence risk for miR-200b (HR [95% CI]=2.04 [1.00, 4.16], P=0.05), miR-203 (HR=4.2 [1.48, 11.93], P=0.007), miR-29a (HR=2.61 [1.34,5.07], P=0.005), and miR-31 (HR=4.03 [1.76, 9.24], P=0.001). Both plasma miR-31 (AUC: 0.717) and miR-29a (AUC: 0.703) could discriminate recurrence from these patients without recurrence. In addition, high levels of miR-31 during ...
UNLABELLED: Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years, 296 participants developed HCC (n=125), GBTC (n=137), or IBD (n=34). Using risk-set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age, sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence rate ratios (IRRs
A Bayesian network model was developed to integrate diverse types of data to conduct an exposure-dose-response assessment for benzene-induced acute myeloid leukemia (AML). The network approach was used to evaluate and compare individual biomarkers and quantitatively link the biomarkers along the exposure-disease continuum. The network was used to perform the biomarker-based dose-response analysis,
Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Journal editors viewpointsSpeaker: John JARCHO, Boston, USA, NEJMDiscussant: Rita REDBERG, San Francisco, USA, Arch Intern MedAbstract : Biomarker studies have proliferated widely, but the actual impact of most such studies on the practice of medicine is modest. One major underlying problem is a lack of clarity (on the part of both investigators and readers) about what biomarker data can be expected to contribute. In many cases, studies merely demonstrate a statistical association between a putative biomarker and a clinical correlate, but the implications of this association are not made explicit. In some cases, there is an expectation that a new biomarker, if found to correlate with disease, will reveal previously unsuspected or unproven aspects of disease pathogenesis; but scientific discovery is achieved by an association study alone. Novel biomarkers may occasionally improve diagnosis, as with high-sensitivity troponin assays, or
Humans have had control over fire for at least the last 1 million years (Berna and others, 2012, PNAS, 109, 20, E1215-E1220). This control is relative, however, as human ignitions can accidentally cause wildfires such as the 2016 Nederland, Colorado fire that started from an improperly doused campfire. In areas that are not naturally fire-prone, biomass burning residue in lake cores is sometimes used as an indicator of the presence of humans in an area. New techniques using specific biomarkers can determine if and when humans lived in a region, and if the presence of humans coincides with increased fire activity.. However, specific biomarkers can help determine the timing and interpretation of climatic and anthropogenic events. For example, changing climate conditions coupled with deforestation, enforced agriculture and/or pastoralism, and the introduction of European diseases may have influenced the ability of residents to continue living in the mountains of northern New Mexico. Fecal sterols ...
SIGNIFICANCE. Oxidative stress is considered to be an important component of various diseases. A vast number of methods have been developed and used in virtually all diseases to measure the extent and nature of oxidative stress, ranging from oxidation of DNA to proteins, lipids, and free amino acids. Recent Advances: An increased understanding of the biology behind diseases and redox biology has led to more specific and sensitive tools to measure oxidative stress markers, which are very diverse and sometimes very low in abundance.. CRITICAL ISSUES. The literature is very heterogeneous. It is often difficult to draw general conclusions on the significance of oxidative stress biomarkers, as only in a limited proportion of diseases have a range of different biomarkers been used, and different biomarkers have been used to study different diseases. In addition, biomarkers are often measured using nonspecific methods, while specific methodologies are often too sophisticated or laborious for routine ...
The analysis of human serum for different biomarkers holds promise for the early detection, diagnosis and treatment of a variety of diseases, such as cystic fibrosis, arthritis and multiple types of cancer. Serum biomarkers can be used as indicators of the state of disease progression or simply as indicators for the functioning of normal biological processes within the human body. Ultimately, these biomarkers can monitor the progress of therapy [1,2]. For routine analysis of only one or a few analytes, the enzyme-linked immunosorbent assay (ELISA) remains the workhorse method for protein analysis in basic research and clinical diagnostics. Owing to increasing efforts in recent years in biomarker discovery [3,4], many high-quality antibodies with high specificity and affinity are becoming available to these markers and to entire proteomes [5-8] for basic research, early detection of cancer and other medical diagnostics [9,10].. Mass spectrometry has emerged as a powerful tool for comprehensive ...
We performed a validation study of 17 preselected plasma protein markers with reported high evidence for the prediction of eGFR decline in patients with type 2 diabetes and incident or early-stage CKD. We showed in an univariable analysis that 9 of the markers had significantly different concentration levels between patients with stable eGFR and fast progression of eGFR decline and that 14 biomarkers significantly contributed to the prediction of eGFR levels. However, most of the predictive ability was attributable to the association with baseline GFR. In the multivariable analysis of eGFR decline over time, only five markers (KIM1, FGF23, NTproBNP, HGF, and MMP1) remained significant but exhibited only a modest predictive power on top of clinical covariates. Furthermore, if the longitudinal analysis was adjusted for baseline eGFR, none of the biomarkers were able to contribute a relevant portion of explained variability, suggesting that baseline eGFR is the key variable in prediction of renal ...
About Cardiac Biomarker. A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L. Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs. The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of ...
Using a prospective cohort study of 2,910 Danish women with invasive breast cancer, we have demonstrated that elevated CRP levels at the time of diagnosis of breast cancer were associated with reduced overall and disease-free survival and with increased risk of death from breast cancer. These are novel observations.. Mechanistically, three components might explain the observed association between elevated CRP levels and poor breast cancer prognosis. First, tumour cell behavior: plasma CRP levels may reflect the aggressiveness of the tumour, that is, plasma CRP levels might sum up some prognostic information of well-known tumour characteristics, such as tumour stage and grade. In the present study, elevated CRP levels were indeed associated with larger tumour size, presence of distant metastases, and lower tumour grade (although CRP was not linearly associated with tumour grade), and these prognostic factors were associated with poor prognosis. Second, adjacent inflammation: plasma CRP levels ...
Cancer-associated blood biomarkers exist in exceedingly low concentrations within complex mixtures of high-abundance proteins such as albumin and immunoglobulins. Moreover, biomarkers in the blood may be subjected to degradation during transportation and storage. Such degradation is a significant source of bias for cancer biomarker measurement and discovery. We have created N-isopropylacrylamide porous sieving core shell smart nanoparticles containing an internal affinity bait to perform three independent functions within minutes, in one step, in solution (serum or plasma): a) molecular size sieving with complete separation from high abundance residence proteins such as albumin and immunoglobulin, b) affinity capture of all solution phase target molecules, and c) complete protection of harvested proteins from enzymatic degradation. The captured analytes can be readily electroeluted for analysis. In our preliminary studies we have manufactured large quantities of uniform porous nanoparticles ...
Inflammatory factors have been associated with increased risk for several cancers; several reviews over the past 10 years describe such associations (1-4). However, past epidemiologic investigations of inflammation and cancer risk have typically been small, utilized varied analysis platforms, and included a narrow range of analytes. For instance, epidemiologic studies of non-Hodgkin lymphoma (5-10), colorectal (11-13), gastric (14, 15), endometrial (16), ovarian (17-21), and lung cancer (22-24) examined a select number of inflammatory markers in various cohorts. Markers evaluated, however, have varied between studies, making interpretation of results difficult. Consequently, the precise molecular markers and pathways involved in carcinogenesis remain unclear.. Multiplex technologies have now been developed to measure larger numbers of inflammatory protein markers using small volumes of serum, plasma, and other specimens (25-31). This has created an opportunity for systematic, large-scale ...
BACKGROUND: There is limited information regarding the role of biomarker levels at predicting mortality in patients with the coronavirus disease (COVID-19) pandemic. The purpose of this study is to determine the differences in serum biomarker levels in adults with COVID-19 who survived hospitalization from those who did not. METHODS: A comprehensive search was completed on PubMed, EMBASE and Cochrane libraries to identify studies of interest. Endpoints of interest were blood counts, hepatic function test, acute phase reactants, cytokines and cardiac biomarkers. RESULTS: A total of 10 studies with 1584 patients were included in the pooled analyses. Biomarkers that were noted to be significantly higher in those who died from coronavirus disease included: white blood cell count, neutrophil count, C-reactive protein, high sensitivity C-reactive protein, procalcitonin, ferritin, D-dimer, interleukin-6, lactate dehydrogenase, creatine kinase, prothrombin time, aspartate aminotransferase, alanine
Evans, M.D., Cooke, M.S., Olinski, R., Gackowski, D., Rozalski, R., Siomek, A., Loft, S., Rossner, Jr. P., Sram, R., Henriksen, T., Poulsen, H.E., Weimann, A., Barbieri, A., Sabatini, L., Violante, F., Kino, S., Ochi, T., Sakai, K., Takeuchi, M., Kasai, H., Meerman, J.H.N., Halliwell, B., Jenner, A.M., Wang, H., Cerda, C., Saez, G., Haghdoost, S., Svoboda, P., Hu, C.-W., Chao, M.-R., Peng, K.-Y., Shih, W.-C., Wu, K.-Y., Orhan, H., Istanbullu, N.S., Mistry, V., Farmer, P.B., Sandhu, J., Singh, R., Cortez, C., Su, Y., Santella, R.M., Lambert, P., Smith, R. (2010). Toward consensus in the analysis of urinary 8-oxo-7,8-dihydro-2′- deoxyguanosine as a noninvasive biomarker of oxidative stress. FASEB Journal 24 (4) : 1249-1260. [email protected] Repository. https://doi.org/10.1096/fj.09- ...
Results After adjustment for covariates, statistically significant linear associations with walking duration were observed for WBC, hsTnT, Cr and CysC. CRP quartiles 1 and 2 showed no significant difference followed by a significant inverse dose-response relationship. A similar pattern, but less pronounced, was seen for N-terminal pro-brain natriuretic peptide. Mean differences between the first two quartiles of CRP and its fourth quartile were 17 min. Between categories 1 (more beneficial) and 4 of WBC, hsTnT, Cr and CysC the differences were 15, 12, 23 and 20 min, respectively.. ...
Purpose: Circulating hormone concentrations are associated with breast cancer risk, with well-established associations for postmenopausal women. Biomarkers may represent minimally invasive measures to improve risk prediction models.. Experimental Design: We evaluated improvements in discrimination gained by adding serum biomarker concentrations to risk estimates derived from risk prediction models developed by Gail and colleagues and Pfeiffer and colleagues using a nested case-control study within the EPIC cohort, including 1,217 breast cancer cases and 1,976 matched controls. Participants were pre- or postmenopausal at blood collection. Circulating sex steroids, prolactin, insulin-like growth factor (IGF) I, IGF-binding protein 3, and sex hormone-binding globulin (SHBG) were evaluated using backward elimination separately in women pre- and postmenopausal at blood collection. Improvement in discrimination was evaluated as the change in concordance statistic (C-statistic) from a modified Gail or ...
Provides device manufacturers and FDA staff with updated recommendations concerning 510(k) submissions for various types of assays for C Reactive Protein (CRP).
Colorectal cancer (CRC) remains a major public health problem with advanced and recurrent disease being a management challenge due to the lack of efficacy of currently available monitoring tools. Carcinoembryonic antigen is used as a marker for recurrent disease but has limited sensitivity. Early sensitive markers of disease severity and recurrence are required. The aim of this thesis was to identify potential metabolic biomarkers of CRC patients using Metabonomics based on proton nuclear magnetic resonance (1H NMR) spectroscopy. The breadth of 1H NMR metabonomics exploring different aspects of CRC pathogenesis was investigated. A global approach profiling a large number of metabolites was undertaken in cell line and chemoprevention studies with subsequent targeted profiling experiments using human polypoid tissue samples. The studies primarily exhibited changes in choline and lipids to be associated with CRC. Although these metabolites are well reported, this thesis presents contemporary ...
We found separated clustering in multivariate analysis (OPLS-DA) between AMI group and control group, and database search was done to find out proper metabolites to distinguish acute MI disease. As a result, several lipids and amino acid were identified as biomarker candidates. Several biomarkers such as LysoPC(18:2), LysoPC(18:1), MG(18:0(9Z)/0:0/0:0) were shown similar intensity change in each CVD disease groups, and this finding might help to find sensitive CVD diagnostic marker ...
hree renal biomarkers, acute kidney injury (AKI), albuminuria, and low estimated glomerular filtration rate (eGFR), considered separately or together, can predict adverse outcomes in diabetes
Past vegetation assemblages, preserved in peat layers, are one of the key proxies when reconstructing historical peatland dynamics. Northern peatlands can be divided into two main types: fens and bogs. Compared with bog peat, the fen peat is usually more decomposed because of different eco-hydrological conditions and effective humification processes. A high level of decomposition hampers reliable identification of plant remains and constrains palaeoecological approaches. Biogeochemical studies on bog plants and bog peat have shown that plant group-specific biomarkers can be applied to identify fossil plants or plant groups from peat, given the identification of plant group-specific markers in living fen plants. In this study, we applied plant macrofossil, biomarkers and multivariate statistical analyses to two mid-boreal peat sequences to investigate whether biomarkers can be applied to distinguish fen and bog environments and whether plant-specific biomarkers can be identified from fen peat. ...